Alchemia, a drug discovery and development company based in Brisbane, Australia, has appointed Thomas Liquard as Chief Executive following the departure of Charles Walker.
Liquard, who joined Alchemia last December as Chief Operating Officer, brings significant commercial and managerial expertise to the company having most recently been Senior Director, Portfolio Development Lead Emerging Markets for the Established Products portfolio at Pfizer in New York, US.
The company has been preparing for its transformation into a broader commercial organisation and Phase III trial data is expected in the first half this year for HA-irinotecan, a potential treatment of metastatic colorectal cancer, in addition to a developing oncology pipeline.
Liquard spent seven years with Pfizer, where he held various commercial roles of increasing scope and responsibility.
Alchemia also markets the FDA-approved drug fondaparinux, an injectible antithrombotic in the US, as well as other major markets through partner Dr. Reddy’s Laboratories.